Karyopharm Therapeutics | KPTI - Umsatzkosten





Umsatzkosten Veränderung Datum
AbbVie USD 4.29B 73M 2026-06
Abbott USD 5.94B 642M 2026-06
Amgen USD 1.87B 271M 2026-06
AstraZeneca USD 2.52B 2.73B 2026-06
BioCryst Pharmaceuticals USD 3.84M 5.68M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Eli Lilly USD 3.27B 309M 2026-06
GlaxoSmithKline GBP 2.07B 192M 2026-06
Incyte USD 104.96M 457K 2026-06
J&J USD 8B 67M 2026-06
Karyopharm Therapeutics USD 1.34M 139K 2026-03
MacroGenics USD 9.53M 585K 2026-03
Merck USD 3.14B 200M 2026-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Novartis USD 3.71B 251M 2026-06
Novartis USD 3.46B 83M 2026-03
Pfizer USD 4.09B 498M 2026-06
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Roche Holding CHF 7.85B 630M 2026-06
Sangamo BioSciences 2.42M 1.11M 2024-06
Takeda JPY 517.6B 42.94B 2026-06
TG Therapeutics USD 41.19M 7.68M 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Xencor USD 61.66M 50.95M 2025-06